The efficient synthesis of a new series of acyclonucleotide analogues with a 1,2,3-triazole linker is described starting from diethyl azidomethyl-, 2-azidoethyl-, 3-azidopropyl-, 4-azidobutyl-, 2-azido-1hydroxyethyl-, 3-azido-2-hydroxypropyl-and 3-azido-1-hydroxypropylphosphonates and selected alkynes under microwave irradiation. Several O,O-diethylphosphonate acyclonucleotides were transformed into the respective phosphonic acids. All compounds were evaluated in vitro for activity against a broad variety of DNA and RNA viruses and cytostatic activity against murine leukaemia L1210, human Tlymphocyte CEM and human cervix carcinoma HeLa cells. Acyclonucleotide 22e exhibited activity against both herpes simplex viruses (HSV-1, HSV-2) in HEL cell cultures (EC 50 ¼ 17 mM) and feline herpes virus (EC 50 ¼ 24 mM) in CRFK cell cultures, while compounds 20k, 21k, 22k and 23k preferentially inhibited proliferation of human T-lymphocyte CEM cells at IC 50 in the 2.8e12 mM range. 1 2 3 4 5 6 7 8 9 10 11 Fig. 3. Nucleoside analogues having natural nucleobases connected to the 1,2,3-triazole ring by a methylene linker. I.E. Głowacka et al. / European Journal of Medicinal Chemistry 70 (2013) 703e722 704 Conformational preferences of phosphonates described in this paper were ascertained by analyses of 1 H, 1 H{ 31 P} and 13 C NMR spectra. Since all vicinal protoneproton couplings within the H 2 Ce CH 2 fragment in phosphonates 21eel were observed around 7 Hz, it was concluded that the rotation around the PCH 2 eCH 2 N bond is fully unrestricted. On the other hand, based on the values of 3 J H1e H2a ¼ 10.0 Hz, 3 J H1eH2b ¼ 2.9 Hz [83] and small values of 3 J PeH2a and 3 J PeH2b (ca. 5.5 Hz) [84, 85] one may deduce that phosphonates 24eel exist in the antiperiplanar conformation 34 which is probably stabilised by the intramolecular hydrogen bond (Fig. 5) . Conformational behaviour of the three-carbon linkers between the diethoxyphosphoryl and substituted 1,2,3-triazole groups in phosphonates 22eel, 25eel and 26eel is primarily governed by the presence of the hydroxy groups. Thus, values of vicinal protone proton couplings within PCH 2 eCH 2 and CH 2 eCH 2 N subunits in 22eel (ca. 7 Hz) can only be observed when free rotation around these bonds is allowed. 2-Hydroxyphosphonates 25eel adopt the H-bond stabilised antiperiplanar conformation 35 along the PCH 2 e CH bond [ 3 J H1aeH2 ¼ 3.9 Hz, 3 J H1beH2 ¼ 8.6 Hz, 3 J PeH2 ¼ 12.0 and 3 J Pe , while the rotation around the CHeCH 2 N bond is unrestricted [ 3 J H2eH3a ¼ 3.0 Hz, 3 J H2eH3b ¼ 7.0 Hz]. To establish a conformational behaviour of 1-hydroxyphosphonates 26ael the extensive NMR studies on 1-hydroxyphosphonate 26i were conducted at 600 MHz. From the values of 3 J H1eH2a ¼ 3.3 Hz, 3 J H1eH2b ¼ 10.9 Hz as well as 3 J PeH2a ¼ 6.1 and 3 J PeH2b ¼ 6.4, 3 J Pe C3 ¼ 15e18 Hz, it is evident that along the PCHeCH 2 bond, this phosphonate exists in the antiperiplanar conformation 36, while based on the values of 3 J H2aeH3a ¼ 3 J H2aeH3b ¼ 8.0 Hz, 3 J H2be H3a ¼ 5.9 Hz and 3 J H2beH3b ¼ 5.9 Hz one may suggest that along the CH 2 eCH 2 N bond in 26i the rotation is almost free. The anticipated full conformational freedom along the tetramethylene linker in the butylphosphonates 23ael is confirmed by the values of 3 J HeH ¼ 7.1 Hz between all methylene groups (Fig. 5) . Scheme 4. Reagents and conditions: a. CuSO 4 Â 5H 2 O (0.05 equiv.), sodium ascorbate (0.1 equiv.), H 2 OeEtOH (1:1), MW, 40e45 C, 10 min. Scheme 5. Reagents and conditions: a. CuSO 4 Â 5H 2 O (0.05 equiv.), sodium ascorbate (0.1 equiv.), H 2 OeEtOH (1:1), MW, 40e45 C, 10 min. Scheme 6. Reagents and conditions: a. propargyl bromide (1.2 equiv.), K 2 CO 3 (1.1 equiv.), DMF, r.t., 24 h, (95%). Scheme 7. Reagents and conditions: a. TMSBr, CH 2 Cl 2 , r.t., 24 h. 183e184 C; IR (KBr): n ¼ 3281, 3057, 2986, 1707, 1665, 1216, 1047 cm À1 ; 1 H NMR (300 MHz, CDCl 3 ): d ¼ 7.95 (s, 1H, HC5 0 ); 5.61 (s, 2H, CH 2 ); 5.08 (t, J ¼ 5.7 Hz, 1H, OH); 4.75 (ddd, J ¼ 14.2 Hz, J ¼ 5.1 Hz, J ¼ 2.6 Hz, 1H, PCCH a H b ); 4.44 (ddd, J ¼ 14.2 Hz, J ¼ 10.0 Hz, J ¼ 5.6 Hz, 1H, PCCH a H b ); 4.28 (dddd, J ¼ 10.0 Hz, J ¼ 8.0 Hz, J ¼ 5.7 Hz, J ¼ 5.1 Hz, 1H, PCH(OH)); 4.21e4.10 (m, 4H, 2Â 7-dimethyl-2,6-dioxopurin-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-hydroxyethylphosphonate 24h. From azide 16 (0.100 g, 0.448 mmol) and N 1 -propargyltheobromine 19h (0.098 g, 0.448 mmol) the phosphonate 24h (0.190 g, 96%) was obtained as a white powder after purification on silica gel with chloroformemethanol (50:1, v/v); m.p.: 166e168 C; IR (KBr): n ¼ 3237, 2989, 1708, 1663, 1235, 1023 cm À1 ; 1 H NMR (600 MHz, CDCl 3 ): d ¼ 7.80 (s, 1H); 7.53 (s, 1H, HC5 0 ); 5.35 (AB, J ¼ 14.6 Hz, 1H, CH a H b ); 5.30 (AB, J ¼ 14.6 Hz, 1H, CH a H b ); 4.79 (ddd, J ¼ 14.2 Hz, J ¼ 6.0 Hz, J ¼ 2.5 Hz, 1H, PCCH a H b ); 4.47 (ddd, J ¼ 14.2 Hz, J ¼ 9.7 Hz, J ¼ 5.2 Hz, 1H, PCCH a H b ); 4.40e4.34 (m, 1H, PCH(OH)); 4.27e4.15 (m, 4H, 2Â POCH 2 CH 3 ); 4.06 (dd, J ¼ 9.4 Hz, J ¼ 5.8 Hz, 1H); 4.01 (s, 3H, CH 3 ); 3.60 (s, 3H, CH 3 ); 1.38 (t, J ¼ 7.0 Hz, 3H, POCH 2 CH 3 ); 1.36 (t, J ¼ 7.0 Hz, 3H, POCH 2 CH 3 ); 13 C NMR (151.5 MHz, 3-dimethyl-2,6-dioxopurin-7-yl)methyl]-1H-1,2,3-triazol-1-yl}-1-hydroxyethylphosphonate 24i. From azide 16 (0.100 g, 0.448 mmol) and N 7 -propargyltheophylline 19i (0.098 g, 0.448 mmol) the phosphonate 24i (0.145 g, 73%) was obtained as a white powder after chromatography on a silica gel column with chloroformemethanol (50:1, v/v); m.p.: 164e165 C; IR (KBr): n ¼ 3264, 3152, 2990, 1705, 1660, 1224, 1025 cm À1 ; 1 H NMR (600 MHz, CDCl 3 ): d ¼ 8.00 (s, 1H); 7.84 (s, 1H, HC5 0 ); 5.62 (AB, J ¼ 15.0 Hz, 1H, CH a H b ); 5.58 (AB, J ¼ 15.0 Hz, 1H, CH a H b ); 4.80 (ddd, J ¼ 14.3 Hz, J ¼ 5.2 Hz, J ¼ 2.7 Hz, 1H, PCCH a H b ); 4.78 (dd, J ¼ 13.3 Hz, J ¼ 5.9 Hz, 1H); 4.49 (ddd, J ¼ 14.3 Hz, J ¼ 10.0 Hz, J ¼ 5.6 Hz, 1H, PCCH a H b ); 4.36e4.28 (m, 1H, PCH(OH)); 4.27e4.16 v); IR (film): n ¼ 3307, 2988, 2909, 1658, 1226; 1048, 776 cm À1 ; 1 H NMR (300 MHz, CDCl 3 ): d ¼ 7.95 (s, 1H); 7.60 (dd, J ¼ 6.6 Hz, J ¼ 3.0 Hz, 1H); 7.33 (ddd, J ¼ 9.3 Hz, J ¼ 6.3 Hz, J ¼ 1.8 Hz, 1H); 6.53 (d, J ¼ 9.0 Hz, 1H); 6.20 (dt, J ¼ 6.6 Hz, J ¼ 0.9 Hz, 1H); 5.18 (AB, J ¼ 14.4 Hz, 1H, CH a H b ); 5.16 (AB, J ¼ 14.4 Hz, 1H, CH a H b ); 4.53 (dd, J ¼ 15.6 Hz, J ¼ 6.6 Hz, 1H, PCCCH a H b ); 4.56e4.34 (m, 2H, PCCHCH a H b ); 4.18e4.03 (m, 4H, 2Â POCH 2 CH 3 ); 2.95 (brs, 1H, OH); 2.07e1.80 (m, 2H, PCH 2 ); 1.33 (t, J ¼ 6.9 Hz, 3H, POCH 2 CH 3 ); 1.32 (t, J ¼ 6.9 Hz, 3H, POCH 2 CH 3 ); 13 C NMR (75.5 MHz, CDCl 3 ): d ¼ 162.2 (s, C]O); 141.8 (s, HC]C); 140.1; 137.8; 125.4 (s, HC]C); 120.2; 106.7; 65.2 (d, J ¼ 2.6 Hz, PCC); 62.2 (d, J ¼ 6.6 Hz, POC); 61.9 (d, J ¼ 6.6 Hz, POC); 55.9 (d, J ¼ 14.9 Hz, PCCC); 44.4; 31.0 (d, J ¼ 139.7 Hz, PC); 16.3 (d, J ¼ 6.0 Hz, POCC); 31 P NMR (121.5 MHz, CDCl 3 ): d ¼ 29.28 ppm. Anal. Calcd. for C 15 H 23 N 4 O 5 P: C, 48.65; H, 6.26; N, 15.13. Found: C, 48.88; H, 6.34; N, 15.00. 4.1.5.52. Diethyl 1-hydroxy-3-(4-{[5-methyl-2,4-dioxopyrimidin-1(2H)-yl]methyl}-1H-1,2,3-triazol-1-yl)propylphosphonate 26b. From azide 18 (0.105 g, 0.443 mmol) and N 1 -propargylthymine 19b (0.073 g, 0.443 mmol) the phosphonate 26b (0.150 g, 84%) was obtained as a white powder after chromatography on a silica gel column with chloroformemethanol (50:1, v/v); m.p.: 169e171 C; IR (KBr): n ¼ 3410, 2989, 2938, 1682, 1225, 1022 cm À1 ; 1 H NMR (300 MHz, CDCl 3 ): d ¼ 9.89 (brs, 1H, NH); 7.87 (s, 1H, HC5 0 ); 7.37 (d, J ¼ 1.0 Hz, 1H, HC]CH); 4.95 (AB, J ¼ 14.9 Hz, 1H, CH a H b ); 4.92 (AB, J ¼ 14.9 Hz, 1H, CH a H b ); 4.63e4.55 (m, 2H, PCCCH 2 ); 4.23e4.09 (m, 4H, 2Â POCH 2 CH 3 ); 3.80 (ddd, J ¼ 10.7 Hz, J ¼ 6.3 Hz, J ¼ 3.3 Hz, 1H, PCH(OH)); 2.40e2.17 (m, 3H, PCCH 2 , OH); 1.91 (d, J ¼ 1.0 Hz, 3H, CH 3 ); 1.33 (t, J ¼ 6.9 Hz, 3H, POCH 2 CH 3 ); 1.30 (t, J ¼ 6.9 Hz, 3H, POCH 2 CH 3 ); 13 C NMR (75.5 MHz, CD 3 OD): d ¼ 166.7 (s, C]O); 152.6 (s, C]O); 142.6; 125.5; 111.6; 65.1 (d, J ¼ 167.8 Hz, PC); 64.4 (d, J ¼ 7.5 Hz, POC); 64.2 (d, J ¼ 7.5 Hz, POC); 47.7 (d, J ¼ 16.1 Hz, PCCC); 43.9; 33.2 (d, J ¼ 4.0 Hz, PCC); 17.0 (d, J ¼ 4.9 Hz, POCC); 16.9 (d, J ¼ 4.9 Hz, POCC); 12.5; 31 P NMR (121.5 MHz, CDCl 3 ): d ¼ 24.76 ppm. CH a H b ); 5.59 (AB, J ¼ 14.9 Hz, 1H, CH a H b ); 4.63e4.55 (m, 2H, PCCCH 2 ); 4.22e4.09 (m, 4H, 2Â POCH 2 CH 3 ); 3.80 (ddd, J ¼ 10.9 Hz, J ¼ 6.2 Hz, J ¼ 3.3 Hz, 1H, PCH(OH)); 3.59 (s, 3H, CH 3 ); 3.43 (s, 3H, CH 3 ); 2.37 (ddddd, J ¼ 14.4 Hz, J ¼ 8.0 Hz, J ¼ 8.0 Hz, J ¼ 6.1 Hz, J ¼ 3.3 Hz, 1H, PCCH a H b ); 2.26 (ddddd, J ¼ 14.4 Hz, J ¼ 10.9 Hz, J ¼ 6.4 Hz, J ¼ 5.6 Hz, J ¼ 5.6 Hz, 1H, PCCH a H b ); 1.35 (t, J ¼ 6.9 Hz, 3H, POCH 2 CH 3 ); 1.33 (t, J ¼ 6.9 Hz, 3H, POCH 2 CH 3 ); 13 C NMR (75.5 MHz, 